A novel combination (“CHAP”) regimen for management of livedoid vasculopathy in 12 patients
Published: 16 June 2022| Version 1 | DOI: 10.17632/6vp4h5yzck.1
Figure 1. Representative before (A) and after (B) images of patient 11 three months after initiation of the "CHAP" regimen (and discontinuation of prednisone and sulfasalazine), showing resolution of painful ulcerations and jagged purpuric macules without formation of new lesions.
University of Pennsylvania